Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?

Insights into Imaging

Table 3 Tumor response and median survival after ⁹⁰Y-RE in HCC patients

Study	Patients (n)	Tumor response on CT^a				Median survival (months)	Microspheres
		CR (%)	PR (%)	SD (%)	PD (%)
Lau et al. (1998)[142]	71	0	27	65	8	9.4	Resin
Dancey et al. (2000) [143]	20 (19 evaluated for response)	5	16	58	21	12.5	Glass
Carr et al. (2004)[144]	65	NR	38	NR	NR	Okuda I: 21.3, Okuda II: 9.9	Glass
Geschwind et al. (2004)[145]	80	NR	NR	NR	NR	Okuda I: 20.6, Okuda II: 12.6	Glass
Goin (2005)[146]	121	NR	NR	NR	NR	Low risk: 15.3, high risk: 3.5	Glass
Salem (2005)[147]	43	NR	47 (79^b)	NR	NR	Okuda I: 24.4, Okuda II: 12.5	Glass
Sangro (2006)[148]	24 (21 evaluated for response)	NR	88^c (PR + SD)		NR	7	Resin
Young (2007)[149]	41	NR	NR	NR	NR	Okuda I: 21.7, Okuda II: 14.2	Glass
Kulik (2008)[150]	108	NR	42.2 (70^b)	34.7	23.1	No PVT: 15.4, branch PVT: 10.0, main PVT: 4.4	Glass

Data of studies including ≥20 patients
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease
PVT = portal vein thrombosis, NR = not reported
^aWHO criteria unless otherwise explained
^bEASL modified WHO criteria[151]
^cRECIST criteria[152]